Abstract
Depression and fatigue are frequent side effects of interferon-α (IFN-α) treatment, and there is compelling evidence that the inflammatory response system (including interleukin-6, IL-6) and the serotonergic system is important in the pathophysiology of such symptoms. Functional polymorphisms in the promoter region of the IL-6 gene (rs1800795) and serotonin transporter gene (5-HTTLPR) have been identified as regulating these systems. The present study aimed to determine if these polymorphisms were associated with the development of depression and fatigue during IFN-α and ribavirin treatment. Ninety-eight Caucasian patients receiving pegylated IFN-α and ribavirin treatment for chronic hepatitis C virus at King's College Hospital, London, and Emory University Hospital, Atlanta, participated in this prospective cohort study. Symptoms of depression and fatigue were measured before treatment and at weeks 4, 8, 12 and 24 during treatment. The ‘low IL-6’ synthesizing genotype (CC) was associated with significantly fewer symptoms of depression (effect size=0.7 at week 24; F=9.4, d.f.=436, P=0.002). The ‘high transcription’ serotonin transporter (5-HTT) genotype (LL) was also associated with significantly fewer symptoms of depression, but with a much smaller effect (effect size=0.2 at week 24; F=4.5, d.f.=436, P=0.03). Neither polymorphisms were associated with symptoms of fatigue (IL-6: F=1.2, d.f.=430, P=0.2; 5-HTT: F=0.5, d.f.=430, P=0.5). The smaller effects of the 5-HTT polymorphism on depression may be explained by an interaction between the genes (F=5.0, d.f.=434, P=0.02): the ‘protective’ effect of the 5-HTTLPR polymorphism was evident only in the presence of the ‘low IL-6’ genotype (F=5.4, d.f.=64, P=0.02), not in the presence of the ‘high IL-6’ genotype (F=2.2, d.f.=369, P=0.1). The association between the IL-6 polymorphism and reduced risk of depressive symptoms confirms the role of the inflammatory response system in the pathophysiology of IFN-α-induced depression; in contrast, the effect of the 5-HTT gene was small and perhaps dependent on the status of the inflammatory response.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.
Maddock C, Landau S, Barry K, Maulayah P, Hotopf M, Cleare AJ et al. Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response. Mol Psychiatry 2005; 10: 332–333.
Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Capuron L, Woolwine BJ et al. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 2005; 19: 23–27.
Loftis JM, Hauser P, Rifai MA . The association between viral clearance and depression in patients with hepatitis C receiving interferon-alpha and ribavirin. Brain Behav Immun 2005; 19: 271–272.
Schafer A, Scheurlen M, Weissbrich B, Schottker K, Kraus MR . Sustained virological response in the antiviral therapy of chronic hepatitis C: is there a predictive value of interferon-induced depression? Chemotherapy 2007; 53: 292–299.
Raison CL, Capuron L, Miller AH . Depressive symptoms and viral clearance: in response. Brain Behav Immun 2005; 19: 273–274.
Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, Bordens R et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998; 58: 2489–2499.
Biro L, Varga L, Par A, Nemesanszky E, Telegdy L, Ibranyi E et al. C5b-9 and interleukin-6 in chronic hepatitis C. Surrogate markers predicting short-term response to interferon alpha-2b. Scand J Gastroenterol 2000; 35: 1092–1096.
Kido M, Kumagai N, Toda K, Tsuchimoto K, Komiyama T . Differential induction of serum interleukin-6 and -12 by interferon-alpha and -beta administration in chronic hepatitis C patients. Hepatol Res 2003; 27: 101–108.
Dantzer R . Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun 2001; 15: 7–24.
Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001; 105: 45–55.
Wichers MC, Kenis G, Leue C, Koek G, Robaeys G, Maes M . Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol Psychiatry 2006; 60: 77–79.
Vollmer-Conna U, Fazou C, Cameron B, Li H, Brennan C, Luck L et al. Production of pro-inflammatory cytokines correlates with the symptoms of acute sickness behaviour in humans. Psychol Med 2004; 34: 1289–1297.
Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 1995; 34: 301–309.
Sluzewska A, Rybakowski J, Bosmans E, Sobieska M, Berghmans R, Maes M et al. Indicators of immune activation in major depression. Psychiatry Res 1996; 64: 161–167.
Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H . Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997; 9: 853–858.
Gaab J, Rohleder N, Heitz V, Engert V, Schad T, Schurmeyer TH et al. Stress-induced changes in LPS-induced pro-inflammatory cytokine production in chronic fatigue syndrome. Psychoneuroendocrinology 2005; 30: 188–198.
Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369–1376.
Fife BL . The role of constructed meaning in adaptation to the onset of life-threatening illness. Soc Sci Med 2005; 61: 2132–2143.
Antonicelli R, Olivieri F, Bonafe M, Cavallone L, Spazzafumo L, Marchegiani F et al. The interleukin-6-174 G>C promoter polymorphism is associated with a higher risk of death after an acute coronary syndrome in male elderly patients. Int J Cardiol 2005; 103: 266–271.
DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M et al. Interleukin-6-174G → C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 2003; 63: 8051–8056.
Wichers MC, Maes M . The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci 2004; 29: 11–17.
King NJ, Thomas SR . Molecules in focus: indoleamine 2,3-dioxygenase. Int J Biochem Cell Biol 2007; 39: 2167–2172.
Wirleitner B, Neurauter G, Schrocksnadel K, Frick B, Fuchs D . Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem 2003; 10: 1581–1591.
Russo S, Kema IP, Fokkema MR, Boon JC, Willemse PH, de Vries EG et al. Tryptophan as a link between psychopathology and somatic states. Psychosom Med 2003; 65: 665–671.
Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 1992; 115 (Part 5): 1249–1273.
Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M . IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005; 10: 538–544.
Mann JJ . Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology 1999; 21: 99S–105S.
Stahl SM . Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 1998; 51: 215–235.
Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386–389.
Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996; 66: 2621–2624.
Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527–1531.
Heinz A, Jones DW, Mazzanti C, Goldman D, Ragan P, Hommer D et al. A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry 2000; 47: 643–649.
Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D et al. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002; 297: 400–403.
Anguelova M, Benkelfat C, Turecki G . A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: II. Suicidal behavior. Mol Psychiatry 2003; 8: 646–653.
Lerer B, Macciardi F . Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. Int J Neuropsychopharmacol 2002; 5: 255–275.
Serretti A, Kato M, De Ronchi D, Kinoshita T . Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007; 12: 247–257.
Nakamura M, Ueno S, Sano A, Tanabe H . The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry 2000; 5: 32–38.
Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Capuron L, Woolwine BJ et al. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 2005; 19: 23–27.
Lewis G, Pelosi AJ, Araya R, Dunn G . Measuring psychiatric disorder in the community: a standardized assessment for use by lay interviewers. Psychol Med 1992; 22: 465–486.
First M, Spitzer R, Gibbon M, Williams J . Structured Clinical Interview for DSM-IV Axis I Disorders. American Psychiatric Association: Washington, DC, 1997.
Maddock C, Baita A, Orru MG, Sitzia R, Costa A, Muntoni E et al. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J Psychopharmacol 2004; 18: 41–46.
Pariante CM, Orru MG, Baita A, Farci MG, Carpiniello B . Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999; 354: 131–132.
Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005; 66: 41–48.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J . An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–571.
Zung WW . A Self-rating Depression Scale. Arch Gen Psychiatry 1965; 12: 63–70.
Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D et al. Development of a fatigue scale. J Psychosom Res 1993; 37: 147–153.
Freeman B, Smith N, Curtis C, Huckett L, Mill J, Craig IW . DNA from buccal swabs recruited by mail: evaluation of storage effects on long-term stability and suitability for multiplex polymerase chain reaction genotyping. Behav Genet 2003; 33: 67–72.
Beitchman JH, Baldassarra L, Mik H, De Luca V, King N, Bender D et al. Serotonin transporter polymorphisms and persistent, pervasive childhood aggression. Am J Psychiatry 2006; 163: 1103–1105.
Yoshida K, Alagbe O, Wang X, Woolwine B, Thornbury M, Raison CL et al. Promoter polymorphisms of the interferon-alpha receptor gene and development of interferon-induced depressive symptoms in patients with chronic hepatitis C: preliminary findings. Neuropsychobiology 2005; 52: 55–61.
Matsuyama N, Mishiro S, Sugimoto M, Furuichi Y, Hashimoto M, Hijikata M et al. The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon. Hepatol Res 2003; 25: 221–225.
Carlo-Stella N, Badulli C, De Silvestri A, Bazzichi L, Martinetti M, Lorusso L et al. A first study of cytokine genomic polymorphisms in CFS: positive association of TNF-857 and IFNgamma 874 rare alleles. Clin Exp Rheumatol 2006; 24: 179–182.
Narita M, Nishigami N, Narita N, Yamaguti K, Okado N, Watanabe Y et al. Association between serotonin transporter gene polymorphism and chronic fatigue syndrome. Biochem Biophys Res Commun 2003; 311: 264–266.
Yamamoto S, Ouchi Y, Onoe H, Yoshikawa E, Tsukada H, Takahashi H et al. Reduction of serotonin transporters of patients with chronic fatigue syndrome. Neuroreport 2004; 15: 2571–2574.
Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26: 643–652.
Schaefer M, Hinzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M et al. Hepatitis C treatment in ‘difficult-to-treat’ psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 2007; 46: 991–998.
Kraus MR, Schafer A, Al Taie O, Scheurlen M . Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005; 12: 96–100.
Capuron L, Raison CL, Musselman DL, Lawson DH, Nemeroff CB, Miller AH . Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 2003; 160: 1342–1345.
Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R . Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002; 7: 468–473.
Neumeister A, Hu XZ, Luckenbaugh DA, Schwarz M, Nugent AC, Bonne O et al. Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry 2006; 63: 978–986.
Moreno FA, Rowe DC, Kaiser B, Chase D, Michaels T, Gelernter J et al. Association between a serotonin transporter promoter region polymorphism and mood response during tryptophan depletion. Mol Psychiatry 2002; 7: 213–216.
Raison CL, Capuron L, Miller AH . Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006; 27: 24–31.
Capuron L, Ravaud A . Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl J Med 1999; 340: 1370.
Rosenstein DL, Lerner D, Cai J, Capuron L, Ravaud A . More on the depressive effects of interferon Alfa. N Engl J Med 1999; 341: 849–850.
Pariante CM, Landau S, Carpiniello B . Interferon alfa-induced adverse effects in patients with a psychiatric diagnosis. N Engl J Med 2002; 347: 148–149.
Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 2006; 78: 815–826.
Acknowledgements
Dr CM Pariante and the UK arm of this study were funded by grants from the Guy's and St Thomas’ Charitable Foundation, the NIHR Specialist Biomedical Research Centre for Mental Health at South London and Maudsley NHS Trust and Institute of Psychiatry (Kings’ College London), the UK Medical Research Council and the NARSAD. The USA arm of the study was funded by grant numbers K05 MH069124 and R01 MH60723 (National Institute of Mental Health), a NARSAD Independent Investigator Award to J Cubells, and by support from the Schering-Plough corporation.
Author information
Authors and Affiliations
Corresponding author
Additional information
Disclosure/Conflict of Interest
Professor AH Miller has served as a consultant or an advisory board member for Schering-Plough and Centocor, and has received research funding from Janssen/Johnson and Johnson, GlaxoSmithKline and Schering-Plough.
Rights and permissions
About this article
Cite this article
Bull, S., Huezo-Diaz, P., Binder, E. et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-α and ribavirin treatment. Mol Psychiatry 14, 1095–1104 (2009). https://doi.org/10.1038/mp.2008.48
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/mp.2008.48
Keywords
This article is cited by
-
Immune targets for therapeutic development in depression: towards precision medicine
Nature Reviews Drug Discovery (2022)
-
Pro-inflammatory markers and fatigue in patients with depression: A case-control study
Scientific Reports (2020)
-
Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis
Rheumatology and Therapy (2020)
-
Moderators for depressed mood and systemic and transcriptional inflammatory responses: a randomized controlled trial of endotoxin
Neuropsychopharmacology (2019)
-
A biocultural approach to psychiatric illnesses
Psychopharmacology (2019)